Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Candel Therapeutics ( (CADL) ).
On June 20, 2025, Candel Therapeutics appointed Charles Schoch as Chief Financial Officer, transitioning from his interim role since January 2024. Schoch has been instrumental in guiding the company through significant financial milestones, including a capital raise of approximately $86 million following positive phase 3 trial results for CAN-2409 in prostate cancer. His appointment is expected to support Candel’s strategic priorities and clinical pipeline advancements, enhancing its market positioning and stakeholder value.
The most recent analyst rating on (CADL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.
Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies aimed at eliciting individualized, systemic anti-tumor immune responses to combat cancer. The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus constructs, with CAN-2409 and CAN-3110 as lead product candidates targeting various cancers.
Average Trading Volume: 975,082
Technical Sentiment Signal: Sell
Current Market Cap: $238M
For a thorough assessment of CADL stock, go to TipRanks’ Stock Analysis page.